Natera's Signatera Assay Shows Promising Results in Cancer Patient Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy NTRA?
Source: stocktwits
Natera Inc. saw its stock rise by 5.15% as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The recent ASCC study findings highlighted the effectiveness of Natera's Signatera assay in managing high-risk cancer patients. The study demonstrated that patients who were ctDNA-negative at baseline had a 100% one-year overall survival rate, while ctDNA-positive patients had only a 63% survival rate. This underscores Signatera's critical role in assessing recurrence risk and guiding personalized treatment strategies.
These promising results from the Signatera assay could enhance Natera's market position and attract further investment, as the clinical value of personalized monitoring strategies becomes increasingly recognized in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 207.740
Low
205.00
Averages
262.92
High
300.00
Current: 207.740
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
Natera Showcases Advances in AI-Driven Genomics at AACR Annual Meeting
- AI-Driven Genomic Analysis: Natera presented a deep learning model for colorectal cancer at the 2026 AACR meeting, trained on data from over 45,000 patients, achieving an AUROC of 0.98, which highlights its potential to transform routine pathology into a scalable genomic profiling platform, thereby accelerating treatment decisions.
- ctDNA Decision Support: A study involving 465 MSI-H metastatic colorectal cancer patients revealed that approximately 40% experienced early ctDNA clearance post-immune checkpoint inhibitor treatment, with Signatera negativity correlating with a 96% three-year overall survival rate, underscoring the technology's significance in cancer treatment.
- Platform Expansion: Natera's tissue-free MRD platform demonstrated strong correlations between ctDNA levels and Signatera quantitative levels across various cancers, with the LatitudeTM assay launched in 2025 and plans for expansion into additional histologies later this year, enhancing its competitive edge.
- Early Cancer Detection: Natera's blood-based screening test showed a sensitivity of 22.5% and specificity of 91.5% for detecting advanced precancerous lesions, covering all histologic subtypes, indicating its potential to redefine early cancer intervention standards.
See More
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
Natera Showcases Advances in AI-Driven Genomics at AACR Annual Meeting
- AI-Driven Genomic Analysis: Natera presented a deep learning model for colorectal cancer at the 2026 AACR meeting, trained on data from over 45,000 patients, achieving an AUROC of 0.98, which highlights its potential to transform routine pathology into a scalable genomic profiling platform, thereby accelerating treatment decisions.
- ctDNA Decision Support: A study involving 465 MSI-H metastatic colorectal cancer patients revealed that approximately 40% experienced early ctDNA clearance post-immune checkpoint inhibitor treatment, with Signatera negativity correlating with a 96% three-year overall survival rate, underscoring the technology's significance in cancer treatment.
- Platform Expansion: Natera's tissue-free MRD platform demonstrated strong correlations between ctDNA levels and Signatera quantitative levels across various cancers, with the LatitudeTM assay launched in 2025 and plans for expansion into additional histologies later this year, enhancing its competitive edge.
- Early Cancer Detection: Natera's blood-based screening test showed a sensitivity of 22.5% and specificity of 91.5% for detecting advanced precancerous lesions, covering all histologic subtypes, indicating its potential to redefine early cancer intervention standards.
See More
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
